Beyond Injectable Metabolic Therapeutics
A category thesis on oral metabolic peptides, gut-lumen biology, and the next therapeutic architecture after the first GLP-1 wave.
Abstract
The whitepaper separates mechanism crowding from architecture crowding. GLP-1 success validates metabolic biology, but it does not exhaust the therapeutic design space for route, exposure, gut-proximal activity, or peptide format.
It frames DPP-4 and GLP-1 biology as early modules in a broader oral metabolic peptide systems thesis, where delivery constraints, local gut activity, modular design, and validation strategy shape the discovery program from the beginning.
Key topics
- Metabolic therapeutics after the first injectable GLP-1 wave.
- Oral-route and gut-lumen peptide opportunities.
- DPP-4, GLP-1, and gut-proximal architecture questions.
- How Peptide Lab can prioritize first validation panels.
Section summaries
Architecture, not only mechanism
Why the next metabolic peptide opportunities may differ by route, exposure, locality, and validation path.
Gut-proximal biology
How oral metabolic peptides could be evaluated around lumen-facing activity, stability, and assay-relevant readouts.
Discovery implications
How a systems thesis can guide candidate generation, filter design, portfolio selection, and partner validation.
Who should request it
- Partners exploring metabolic peptide opportunities.
- Investors evaluating post-GLP-1 architecture theses.
- Teams considering oral-route or gut-proximal discovery programs.
Ask for the whitepaper
Share a few details and Metastate will review the request before sending the PDF manually. The whitepaper is not available as an automatic public download.
Form submissions are processed through Formspree. See the privacy policy for data handling details.